Bradley Campbell – President & COO, Amicus Therapeutics
Brad Campbell, president and COO of US rare disease specialist Amicus, talks domestic and global product launches, the company’s first steps into the gene therapy space, and how a biotech…
Company Name: BOC Sciences
Telephone Number: 1-631-485-4226
Brad Campbell, president and COO of US rare disease specialist Amicus, talks domestic and global product launches, the company’s first steps into the gene therapy space, and how a biotech…
Tatsuya Kaihara, head of US operations for Japanese eyecare specialist Santen, describes his excitement at bringing two new ophthalmic advancements to the US market, the similarities, differences, and synergies of…
The US heads for three leading international mid-cap innovators – Japanese firms Eisai and Kyowa Kirin and Danish outfit Lundbeck – explain their vital role leading operations in the world’s…
Ahead of the 2020 US National Organization for Rare Disorders (NORD)’s Rare Diseases and Orphan Products Breakthrough Summit, NORD president and CEO Peter L. Saltonstall outlines his hopes for the…
Certara’s Ulrich Neumann looks at the challenges that payment models for cell and gene therapy (CGT) have faced, the multiple models now under development, and why an open and collaborative…
Gary Zieziula, president & region head North America for Kyowa Kirin, a specialty care-focused Japan-based global pharma company, highlights the tremendous growth the affiliate has seen over the past three…
The USA is now Switzerland’s biggest export market and in 2019 Switzerland exported more to the US than to France, Italy, the UK and Austria combined and twice as much…
In the aftermath of the fiery first presidential debate between incumbent Donald Trump and Democratic Party rival Joe Biden, we round up the latest on how the latest developments in…
Dr Peter Marks MD, PhD, director of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), highlights the Center’s contributions related to the…
Regular PharmaBoardroom contributor Brendan Shaw weighs in on the potential implications for US pharma of President Donald Trump’s latest executive order on medicine pricing, its wider impact on other high…
As part of our upcoming US Healthcare and Life Sciences Review, we spoke to key stakeholders – former Association for Accessible Medicines (AAM) president & CEO Chip Davis; Carol Lynch,…
In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment aducanumab’s torturous journey to market, Dr Neil Cashman highlights what the next steps in the process…
See our Cookie Privacy Policy Here